US9428755B2 - Use of clostridial methyltransferases for generating novel strains - Google Patents
Use of clostridial methyltransferases for generating novel strains Download PDFInfo
- Publication number
- US9428755B2 US9428755B2 US14/592,208 US201514592208A US9428755B2 US 9428755 B2 US9428755 B2 US 9428755B2 US 201514592208 A US201514592208 A US 201514592208A US 9428755 B2 US9428755 B2 US 9428755B2
- Authority
- US
- United States
- Prior art keywords
- dna
- vector
- methyltransferase
- polynucleotide
- bacterial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
- C12N9/1007—Methyltransferases (general) (2.1.1.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2521/00—Reaction characterised by the enzymatic activity
- C12Q2521/30—Phosphoric diester hydrolysing, i.e. nuclease
- C12Q2521/331—Methylation site specific nuclease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y201/00—Transferases transferring one-carbon groups (2.1)
- C12Y201/01—Methyltransferases (2.1.1)
- C12Y201/01072—Site-specific DNA-methyltransferase (adenine-specific) (2.1.1.72)
Definitions
- the present invention relates to isolated polynucleotides encoding DNA Type I methyltransferase and uses thereof for improving transformation efficiencies of exogenous and endogenous plasmid DNA into Clostridia.
- Clostridia which include species of medical and industrial importance have historically been difficult to manipulate genetically. Those that have been genetically transformed are few and the efficiencies have been low, typically limited to at most 1 ⁇ 10 3 transformants/ ⁇ g DNA in the most efficient systems (Mermelstein et al., 1993 , Applied and Environmental Microbiology, 59:1077-1081; Allen and Blaschek, 1990, FEMS Microbiology Letters, 58:217) but more often only yield a few recombinant colony forming units (CFU). Integrative plasmids have been used with even less efficiency, typically attaining transformation frequencies no higher than 1 CFU/ ⁇ g DNA.
- the prevailing view is that the low transformation frequencies are due to the introduced DNA being degraded during the transformation process by one or more host restriction systems. In those cases where suitable transformation efficiencies in Clostridium have been observed and shown to be reproducible, it was often due to blocking of a specific endonuclease site encoding a restriction enzyme (e.g., CacI, C. acetobutylicum ).
- a restriction enzyme e.g., CacI, C. acetobutylicum
- the present invention relates to using Clostridial Type I methyltransferases to improve the efficiency of introducing DNA into solventogenic Clostridia.
- isolated polynucleotides encoding a DNA Type I methyltransferase selected from the group consisting of: a polynucleotide comprising a nucleotide sequence having at least 98% sequence identity with SEQ ID NO: 1; and (b) a polynucleotide encoding a polypeptide having an amino acid sequence at least 85% sequence identity with the polypeptide SEQ ID NO: 2 are provided.
- the invention provides an isolated polynucleotide encoding a DNA Type I methyltransferase selected from the group consisting of: (a) a polynucleotide comprising a nucleotide sequence having at least 85% sequence identity with SEQ ID NO: 3; and (b) a polynucleotide encoding a polypeptide having an amino acid sequence at least 87% sequence identity with the polypeptide of SEQ ID NO: 4.
- the invention provides an isolated polynucleotide expressed from an operably-linked promoter, phosphotransacetylase-acetate kinase operon (Ppta-ack) and a polynucleotide encoding a polypeptide having an amino acid sequences at least 60% sequence identity with the polypeptide of SEQ ID NO: 7.
- Ppta-ack phosphotransacetylase-acetate kinase operon
- the polynucleotide is encoded on a methylation vector such as pCOSMTI-1, pCOSMTI-2 or pCOSMTI-12.
- the isolated polynucleotide is expressed from an operably-linked promoter such as Ppta-ack.
- the methyltransferase of SEQ ID NO: 1 is expressed with a polynucleotide consisting of the nucleotides 1-296 of SEQ ID NO: 5.
- the methyltransferase of SEQ ID NO: 3 is expressed with a polynucleotide consisting of the nucleotides 1-296 of SEQ ID NO: 6.
- the methyltransferase of SEQ NO: 7 is expressed with a polynucleotide consisting of the nucleotides 1-296 of SEQ ID NO: 6.
- the invention provides methods of generating a bacterial recombinant cell expressing a DNA Type I methyltransferase having biological activities, comprising: (a) introducing a methylation vector into a bacterial host cell wherein said methylation vector expresses a DNA Type I methyltransferase polynucleotide; and (b) introducing a transforming vector into the bacterial host cell wherein said transforming vector comprises plasmid DNA that is methylated by said methylation vector.
- the DNA Type I methyltransferase polynucleotide is a polynucleotide comprising a nucleotide sequence having at least 98% sequence identity with SEQ ID NO:1, a polynucleotide encoding a polypeptide having an amino acid sequence at least 85% sequence identity with the polypeptide SEQ ID NO: 2, a polynucleotide comprising a nucleotide sequence having at least 85% sequence identity with SEQ ID NO: 3, or a polynucleotide encoding a polypeptide having an amino acid sequence at least 87% sequence identity with the polypeptide of SEQ ID NO: 4.
- the DNA Type I methyltransferase polynucleotide is expressed from an operably-linked promoter such as Ppta-ack.
- the DNA Type I methyltransferase is encoded on a methylation vector such as pCOSMTI-1, pCOSMTI-2 or pCOSMTI-12.
- the bacterial host cell is Escherichia coli ( E. coli ).
- the second bacterial recipient cell is Clostridia.
- the method further comprises purifying and transferring the methylated plasmid DNA from the bacterial host cell to a second bacterial recipient cell that can degrade the plasmid DNA but which cannot degrade the methylated DNA.
- the methylated plasmid DNA is transferred from the bacterial host cell to a second bacterial recipient cell by transformation such as electroporation or conjugation.
- the transformants of the methylated DNA of the second bacterial host cell comprising methylated DNA are isolated.
- the methylation vector is transformed into the bacterial host cell along with a shuttle vector such as pACR-1.
- the methylation vector is transformed into the bacterial host cell with a conjugation vector such as pACC-1.
- FIGS. 1A and 1B show the genomic (a) and amino acid (b) sequences of Mtase I-1 Type I methyltransferase (MTI-1) identified in the C. coskatii genome sequence (SEQ ID NOs: 1 and 2, respectively).
- FIGS. 2A and 2B show the genomic (a) and amino acid (b) sequences of Mtase 1-2 Type I methyltransferase (MTI-2) identified in C. coskatii (SEQ ID NOs: 3 and 4, respectively).
- Mtase 1-2 Type I methyltransferase (MTI-2) identified in C. coskatii (SEQ ID NOs: 3 and 4, respectively).
- FIG. 3 shows the genomic sequence of a methyltransferase operon expressed from the Clostridial Pptaack promoter.
- FIG. 4 shows a plasmid map of methylation vector pCOSMTI-1.
- FIG. 5 shows a plasmid map of methylation vector pCOSMTI-2.
- FIG. 6 shows a plasmid map of doubly methylating vector pCOSMT-12.
- FIGS. 7A-7B show plasmid maps of replicating vectors E. coli - Clostridium shuttle vectors pACR1 (A) and pACR1Cm (B) containing catP, encoding chloramphenicol resistance.
- FIGS. 8A-8B show plasmid maps of conjugation vectors pACC-1 (A) and pACC-1T (B) containing tetR, encoding tetracycline resistance.
- FIG. 9 is a Tris-Borate-EDTA gel showing the co-residency of pCOSMTI-1, pACR-1 and pCOSMTI-12, pACC-1 in E. coli using restriction analysis.
- the arrow at left points to a DNA standard of 1500 base pairs.
- FIG. 10 shows a plasmid map of a Type II methylating control vector pCOSMTII-1.
- This invention provides isolated polynucleotides encoding DNA Type I methyltransferase and uses thereof for improving transformation efficiencies of exogenous and endogenous plasmid DNA into Clostridial hosts.
- This invention further provides plasmid vectors that employ plasmids and sequence compositions that contain homoacetogen Type I methyltransferases expressed from a homoacetogenic Clostridial promoter known to function in E. coli and solventogenic Clostridia.
- transformation efficiency is significantly reduced by host endonucleases that rapidly degrade foreign DNA introduced by various methods known to those skilled in the art (e.g. electroporation, conjugation, protoplast fusion, etc.).
- host endonucleases that rapidly degrade foreign DNA introduced by various methods known to those skilled in the art (e.g. electroporation, conjugation, protoplast fusion, etc.).
- one approach to enhance transformation frequency is to modify the DNA before introduction into the recipient cells so that the introduced DNA becomes recalcitrant to degradation.
- the restriction modification system (R/M system) is used by bacteria, and perhaps other prokaryotic organisms to protect themselves from foreign DNA, such as the one borne by bacteriophages. Bacteria have restriction enzymes which cleave double stranded DNA at specific points into fragments, which are then degraded further by other endonucleases and exonucleases. Approximately one quarter of known bacteria possess R/M systems and of those about one half have more than one type of system. The following solventogenic Clostridia have multiple, diverse R/M systems: C. coskatii, C. autoethanogenum, C. ragsdalei, C. carboxidivorans, C. ljungdahlii.
- solventogenic Clostridia includes Clostridia that have the ability to make solvents such as ethanol either directly in the metabolic pathway or by the reduction of acetate.
- Type II restriction systems Feyter et al. 1990 , Journal of Bacteriology, 173:6421-6427; Mann et al., 1978, Gene 3:97-102
- Type II restriction systems Feyter et al. 1990 , Journal of Bacteriology, 173:6421-6427; Mann et al., 1978, Gene 3:97-102
- These enzymes recognize a palindromic sequence and upon binding the duplex DNA in the presence of magnesium ions, digest the DNA across both strands at or very near the site of binding. The digestion can generate a blunt end or asymmetrical cleavages with 5′ or 3′ overhangs.
- DNA Type I restriction endonucleases bind the DNA at a specific recognition site on the DNA but cut at a significant distance from the recognition site.
- DNA Type I (EC 3.1.21.3) restriction and modification enzymes are complex multifunctional systems that require ATP, S-adenosylmethionine, and Mg 2+ as cofactors. They catalyze the endonucleolytic cleavage of DNA to give random, bipartite, interrupted double-stranded fragments with terminal 5′-phosphates. ATP is simultaneously hydrolysed. These systems are widespread in Clostridium .
- the Type I restriction systems contain all the intact genes for a fully functioning restriction-modification system (specificity, methyltransferase and restriction genes) and thus are presumed to be playing an important role in exogenous DNA degradation.
- DNA Type I methyltransferase as used herein is a DNA N-6 adenine methyltransferase (E.C. 2.1.1.72).
- a Type I methyltransferase is an enzyme that recognizes a specific sequence and methylates one of the adenine bases in or near that sequence (Kennaway et al. 2009 , Nucleic Acids Research , The structure of M.EcoKI Type I DNA methyltransferase with a DNA mimic antirestriction protein, 37(3):762-770). Foreign DNAs which are not methylated in this manner that are introduced into the host cell are degraded by sequence-specific restriction enzymes.
- the Type I methylation system comprises the protective component of the restriction-modification system.
- the Type I methyltransferases are expressed from a known constitutive Clostridial promoter in E. coli host strains methylating the DNA at unknown recognition sequences.
- the DNAs contained in solventogenic Clostridia are all AT rich (>70%) and therefore abundant targets exist for the methyltranferase activities encoded by the DNA modification enzymes described herein.
- the isolated polynucleotide encoding the DNA Type I methyltransferase is encoded by a nucleotide sequence comprising a nucleotide sequence having at least 98% sequence identity with SEQ ID NO: 1, a polynucleotide encoding a polypeptide having an amino acid sequence at least 85% sequence identity with the polypeptide SEQ ID NO: 2, a polynucleotide comprising a nucleotide sequence having at least 85% sequence identity with SEQ ID NO: 3, or a polynucleotide encoding a polypeptide having an amino acid sequence at least 87% sequence identity with the polypeptide of SEQ ID NO: 4.
- the DNA Type I methyltransferase is encoded by a polynucleotide that hybridizes under high stringency conditions with nucleotides 1-1446 of SEQ ID NO: 3 or its full-length complimentary strand or a polynucleotide that hybridizes under high stringency conditions with nucleotides 1-1446 of SEQ ID NO: 3 or its full-length complimentary strand.
- the isolated polynucleotide encoding the DNA Type I methyltransferase can be expressed using a strong constitutive Clostridial promoter such as Pptaack.
- the polynucleotide expressed from an operably linked promoter is a polynucleotide having an amino acid sequences at least 60% sequence identity with the polypeptide of SEQ ID NO: 7 or a polynucleotide that hybridizes under high stringency conditions with nucleotides 1-2864 of SEQ ID NO: 7 or its full-length complimentary strand.
- high stringency conditions refers to conditions under which the polypeptide will hybridize to a target sequence.
- high stringency conditions include hybridization at 50° C. in 5 ⁇ SSPE, 0.25% SDS and washed 2 times in hybridization wash buffer composed of 2 ⁇ SSC, 0.2% SDS at 65° C.
- operably-linked means joined as part of the same nucleic acid molecule, suitably positioned and oriented for transcription to be initiated from the promoter.
- DNA operably linked to a promoter is under transcriptional initiation regulation of the promoter or in functional combination therewith.
- the isolated polynucleotides encoding DNA Type I methyltransferase can be used in methods to generate a bacterial host recombinant cell expressing a DNA Type I methyltransferase having biological activities.
- the method comprises introducing a methylation vector into the bacterial host cell.
- a methylation vector is a plasmid vector containing a cloned Type I methyltransferase polynucleotide from a homoacetogenic Clostridium .
- Suitable methylation vectors include, but are not limited to pCOSMTI-1 (comprising a cloned MTI-1 Type I methyltransferase polynucleotide), pCOSMTI-2 (comprising a cloned MTI-2 Type I methyltransferase polynucleotide) and pCOSMTI-12 (comprising cloned MTI-1 and MTI-2 Type I methyltransferase polynucleotides).
- the sequences of the cloned Type I methyltransferase can be expressed in E.
- the method further comprises introducing a transforming vector into the bacterial host cell wherein said transforming vector comprises plasmid DNA that is methylated by said methylation vector.
- Suitable bacterial host cells containing the methylation vectors include but are not limited to gram negative bacteria such as E. coli and closely related Enterobacteriaceae including Salmonella spp., Yersinia spp., Klebsiella spp. Shigella spp. Enterobacter spp., Serratia spp. and Citrobacter spp.
- gram negative bacteria such as E. coli and closely related Enterobacteriaceae including Salmonella spp., Yersinia spp., Klebsiella spp. Shigella spp. Enterobacter spp., Serratia spp. and Citrobacter spp.
- the methyltransferase polynucleotides can also be expressed from a replicating broad-host range vector based on the pBBR-1 replicon, originally isolated from Bortadella bronchiseptica S87 (Antoine. and Locht. (1992) Mol. Microbiol. 6(13): 1785-1799).
- the range of genera known to stably replicate pBBR-1-based plasmids includes representatives from Aeromonas, Acetobacter, Agrobacterium, Alcaligenes, Azorizobium, Bartonella, Bordetella, Brucella, Caulobacter, Escherichia, Hyphomicrobium, Methylobacillus, Methylbacterium, Methylophilus, Pseudomonas. Paracoccus, Rhizobium, Rhodobacter Salmonella Vibrio and Xanthomonas.
- a vector In molecular cloning, a vector is a DNA molecule used as a vehicle to artificially carry native or foreign genetic material into another cell, where it can be replicated and/or expressed.
- a vector containing foreign DNA is termed recombinant DNA.
- the four major types of vectors are plasmids, viral vectors, cosmids, and artificial chromosomes. Common to all engineered vectors are an origin of replication, a multicloning site, and a selectable marker.
- the methylation vector and the transforming vector can be first transferred into an E. coli methylation-minus strain GM2163. Co-residing vectors in this host environment will be methylated only to the extent of Type I methyltransferase expression and sequence recognition. Cloned sequences will contain homoacetogenic Clostridial DNA so methylated sites are expected to be present.
- the methylation vector and the transforming vector can also be transferred into E. coli BL21, which is deficient in dcm methyltransferase activity, but contains dam methyltransferase activity.
- the host environment methylates at the adenine N-6 position in the sequence GATC but not at the C-5 position of cytosine in the sequence CCWGG. High frequency transformation will rely on additional modifications to the transforming DNA.
- Type I DNA methylation vectors can also be transformed with general replication and conjugative vectors.
- the bacterial host cell is transformed with a homoacetogen methylation vector, such as pCOSMTI-2, pCOSMTI-1 or pCOSMTI-12, and an E. coli -Clostridial shuttle vector such as pACR-1 to generate a uniquely methylated transforming vector.
- a shuttle vector is a vector constructed so that it can propagate in two different host species. Therefore, DNA inserted into a shuttle vector can be tested or manipulated in two different cell types.
- the cell types are bacterial hosts expressing specific Type I methyltransferases that modify the DNA. The main advantage of these vectors is they can be manipulated in E.
- homoacetogen methylation vector such as pCOSMTI-2, pCOSMTI-1 or pCOSMTI-12 are transformed with a conjugation vector such as pACC-1.
- the transforming DNA will be integrated into the bacterial recipient cell chromosome.
- modification of the transforming vector which may or may not contain a replicon, would benefit from the instant invention.
- the methylated DNA from the transforming factor can be purified from the bacterial host cell and transferred to a recipient cell that can degrade the plasmid DNA but which cannot degrade the methylated DNA.
- the purified DNA can be transferred to the recipient cell by methods of transformation, such as transduction, conjugation, and electroporation.
- a recipient cell is a bacterial cell into which exogenous methylated DNA is introduced.
- Bacterial conjugation as relates to the present invention is the natural transfer of genetic material contained on plasmids between bacterial cells by direct cell-to-cell contact or by a bridge-like connection between two cells. It is a mechanism of horizontal gene transfer as are transformation and transduction although these two other mechanisms do not involve cell-to-cell contact.
- a donor cell is a bacterial cell that transfers DNA by conjugation to another bacterial cell.
- Electroporation or electropermeabilization is a significant increase in the electrical conductivity and permeability of the cell plasma membrane caused by an externally applied electrical field. It is usually used in molecular biology as a way of introducing some substance into a cell, such as loading it with a molecular probe, a drug that can change the cell's function, or a piece of coding DNA such as an expression vector.
- Suitable transforming vectors contain an antibiotic resistance marker for selection in both the methylating bacterial host cell and the recipient bacterial cell along with a gram-negative or gram positive replicon and the cloned MtaseI-1 or the MtaseI-2 polynucleotide.
- the transforming vector can also include a transposon expressed in the bacterial recipient cell.
- the vectors When methylation vectors are transformed with general replication and/or conjugative vectors, the vectors can be purified and transformed together into the bacterial recipient cell for additional protection upon entry into the recipient cell.
- the promoter in this embodiment is the Ppta-ack, which is highly expressed in both the host and recipient cells.
- the co-residing vectors may first be separated and then only the modified transforming vector transferred to the bacterial recipient cell.
- C. coskatii genome sequence was performed using the ERGO bioinformatics suite (Integrated Genomics, Arlington Heights, Ill.) and BLASTX. The analysis revealed genes involved in a complex restriction and modification system, which includes Type I, II, and III methyltransferases. Additionally, several methyl-directed endonucleases were identified. These systems target specific DNA sequences containing methylated adenines and cytosines followed by restriction.
- Clostridium autoethanogenum strain DSM10061 [Abrini J, Naria H, Nyns E-J, Clostridium autoethanogenum , sp. Nov. an anaerobic bacterium that produces ethanol from carbon dioxide. Arch. Microbiol. 1994, 4:345-351], C. ragsdalei P11 (ATCC BAA-622) [Hunhke R L, Lewis R S, Tanner R S: Isolation and characterization of novel Clostridial species. International patent 2008, WO 2008/028055 ], C.
- coli COSMTI-1 is GM2163 containing pCOSMTI-1 and a transforming vector
- E. coli COSMTI-2 is GM2163 containing pCOSMTI-2 and a transforming vector
- E. coli COSMTI-12 is GM2163 containing pCOSMTI-12 and transforming vector.
- E. coli was grown in LB medium which was composed of 10 g per liter tryptone, 5 g per liter of yeast extract and 10 g per liter NaCl.
- LB ampicillin medium was composed of LB medium containing filter sterilized 100 ⁇ g ampicillin sulfate per ml.
- E. coli was grown on 2 ⁇ YT agar which is composed of 16 g per liter tryptone, 10 g per liter yeast extract and 5.0 g per liter NaCl.
- 2 ⁇ YT ampicillin (Ap), chloramphenicol (Cm), kanamycin (Kn), tetracycline (Tc), erythromycin (Em) plates were composed of 2 ⁇ YT agar (1.5%) containing 100 ⁇ g (Ap), 25 ⁇ g (Cm), 50 ⁇ g (Kn), 10 ⁇ g (Tc) and 40 ⁇ g (Em) per ml of agar.
- C. coskatii fermentation medium was made anaerobically from concentrated vitamin, mineral and metals stocks with the compositions shown in Tables 1 and 2a-d.
- C. coskatii plating medium was composed of fermentation medium containing 5 g per liter fructose (filter-sterilized and added post autoclaving), 10 g per liter yeast extract and 15-20 g per liter agar.
- Nitrilotriacetic acid 2.0 Adjust the pH to 6.0 with KOH MnSO 4 •H 2 O 1.0 Fe(NH 4 ) 2 (SO 4 ) 2 •6H 2 O 0.8 CoCl 2 •6H 2 O 0.2 ZnSO 4 •7H 2 O 1.0 NiCl 2 •6H 2 O 0.2 Na 2 MoO 4 •2H 2 O 0.02 Na 2 SeO 4 0.1 Na 2 WO 4 0.2
- Vitamin Solution Components Concentration (mg/L) Pyridoxine•HCl 10 Thiamine•HCl 5 Riboflavin 5 Calcium Pantothenate 5 Thioctic acid 5 p-Aminobenzoic acid 5 Nicotinic acid 5 Vitamin B12 5 Mercaptoethanesulfonic acid 5 Biotin 2 Folic acid 2
- MTI-1 Type I Methyltransferase was identified as part of a 7.33 kb operon containing the restriction subunits (R), specificity (S) and methylation (M) genes.
- the nucleotide sequence (SEQ ID NO: 1) and deduced amino acid sequence (SEQ ID NO: 2) of the Clostridium coskatii MTI-1 Type I methyltransferase are shown in FIGS. 1A and 1B .
- the MTI-1 coding sequence is 1419 bp including the stop codon.
- the DNA and deduced amino acid sequences of MTI-1 Type I methyltransferase were compared to protein sequences using BLASTX. The best match was to a Type I N-6 methyltransferase from C.
- MTI-2 Type I Methyltransferase was identified as part of a 6.887 kb operon containing the restriction subunits (R), specificity (S) and methylation (M) genes.
- the nucleotide sequence (SEQ ID NO: 3) and deduced amino acid sequence (SEQ ID NO: 4) of the Clostridium coskatii MTI-2 Type I methyltransferase are shown in FIGS. 2A and 2B .
- the coding sequence is 1446 bp including the stop codon.
- the DNA and deduced amino acid sequences of the MTI-2 Type I methyltransferase were compared to protein sequences using BLASTX. The best match was to a Type I N-6 methyltransferase from Clostridium Maddingley (87% identity) ZP 11365985.1.
- the major protein motif was hsdM-adoMET over the majority of the translated protein.
- the 1419 bp open reading frame encoding MTI-1 along with a 296 bp promoter region Pptaack and 227 bp downstream of the gene were synthesized.
- the coding sequence was operably linked to the Pptaack promoter region and included a standard ribosome-binding site located 12 bp upstream from the translational start site. This promoter has been shown to be constitutively expressed at high levels in E. coli using promoterless antibiotic resistance genes.
- Gene synthesis was performed by Life Technologies/Gene Art Josef-Engert Str. II 93053 Regensburg Germany.
- the methyltransferase sequences were amplified by high-fidelity PCR, constructed in E.
- the 1.942 kb MTI-1 cassette was released by HindIII digestion of pAC80, gel purified using the Qiaex kit (Qiagen, Hilden Germany) and ligated to calf-alkaline phosphotased pACYC184 that was previously digested with HindIII. Ligation mixtures were electroporated into competent E. coli DH10B host cells. Recombinant clones were selected on 2 ⁇ YT agar plates containing tetracycline (5 ⁇ g/ml) and chloramphenicol (25 ⁇ g/ml). Recombinants were screened with HindIII for the inserted MTI-1 expression cassette sequence. The final methyltransferase construct is shown in FIG. 4 and was designated pCOSMTI-1.
- the 1446 bp open reading frame encoding MTI-2 along with the 296 bp promoter region and 233 bp downstream from the MTI-2 gene were synthesized.
- the coding sequence was operably linked to the Pptaack promoter as described in Example 3.
- Gene synthesis was performed by Life Technologies/Gene Art Josef-Engert Str. II 93053 Regensburg Germany. After construction of the complete 1.975 kp expression cassette the sequence was verified using an ISO 9001:2008-certified quality management system and Applied Biosystems Genetic Analyzers. Synthesized DNA was subcloned into a M19/pUC-based vector with suitable engineered sites at the 5′ end for later cloning steps. This vector was designated pAC82.
- the 1.975 kb cassette containing the Pptaack-MTI-2 polynucleotide in pAC82 was digested with BamHI and ligated to calf-alkaline phosphotased pACYC184 previously digested with the same enzyme.
- Clones were initially selected on 2 ⁇ YT agar plates supplemented with chloramphenicol (25 ⁇ g/ml) and counter-selected on tetracycline (5 ⁇ g/ml) plates to verify sensitivity.
- Recombinant E. coli clones that displayed chloramphenicol resistance and tetracycline sensitivity were screened further by restriction analysis.
- Clones were screened using BamHI, HindIII and EcoRI and those that displayed the predicted restriction pattern confirmed the cloned Pptaack-MTI-2 cassette and were used in later experiments.
- the construct is shown in FIG. 5 and was designated pCOSMTI-2.
- C. coskatii MTII-1 (identified as greater than 90% DNA sequence conserved in C. autoethanogenum, C. ljungdahlii , and C. ragsdalei ) along with a 296 bp promoter region (Ppta-ack) and 231 bp downstream of the C. coskatii gene were synthesized.
- the coding sequence was operably linked to the Pptaack promoter region and included a standard ribosome-binding site located 12 bp upstream from the translational start site as described above for the other Type I methyltransferase expression vectors. Gene synthesis was performed by Life Technologies/Gene Art Josef-Engert Str.
- methyltransferase sequences were amplified by high-fidelity PCR, constructed in E. coli replicating vectors, subcloned and end-ligated to remove any overhangs to generate a clean sequence. After construction of the complete 2.198 kp expression cassette the sequence was verified using an ISO 9001:2008-certified quality management system and Applied Biosystems Genetic Analyzers. Synthesized expression DNA containing the MTII-1 polynucleotide was ligated into a M19-pUC-based vector with suitable engineered sites at the 5′ end for downstream cloning and was designated pAC81.
- the 2.198 kb MTII-1 cassette was released by HindIII digestion of pAC81, gel purified using the Qiaex kit (Qiagen, Hilden Germany) and ligated to calf-alkaline phosphotased pACYC184 that was previously digested with HindIII. Ligation mixtures were electroporated into competent E. coli DH10B host cells. Recombinant clones were selected on 2 ⁇ YT agar plates containing tetracycline (10 ⁇ g/ml) and chloramphenicol (50 ⁇ g/ml). Recombinants were screened with HindIII for the inserted MTII-1 expression cassette sequence. The final methyltransferase construct is shown in FIG. 10 and was designated pCOSMTII-1.
- Vector pCOSMTI-12 is an E. coli replicating vector containing both MTI-1 and MTI-2 Clostridial Type I methyltransferases expressed from an operably-linked Clostridial promoter.
- Vector pCOSMTI-12 was generated using pAC80 and pAC82 as source DNA.
- a HindIII site located immediately downstream of the MTI-1 ORF was used as the cloning site for insertion of the MTI-2 Type I methyltransferase polynucleotide.
- Vector pAC80 was digested with HindIII (Fermentas, Vilnius) and the 5′ ends dephosphorylated with fast calf alkaline phosphatase (Fermentas, Vilnius) according to the manufacturer's instructions.
- the dephosphorylated vector was purified using the Qiaex kit.
- Vector pAC82 was digested with HindIII to release the 1.715 kb MTI-2 polynucleotide and gel purified using the Qiaex kit.
- the MTI-2 polynucleotide was ligated to pAC80 using rapid T4 DNA ligase (Fermentas, Vilnius) according to the manufacturer's instructions.
- Ligation mixtures were purified using isopropanol precipitation (at 0.8 volume) at ⁇ 20° C. for 1 hour, centrifuged at room temperature at 12,000 ⁇ g in a microfuge, and followed by a 70% ethanol wash to dry the DNA.
- Ligated DNA was resuspended in 10 ⁇ l of Tris buffer, pH 8.0. Electrocompetent E. coli DH10B was transformed with 1 ⁇ l of the ligation mix at 2.5 kV and transformants were selected on 2 ⁇ YT agar plates for tetracycline and chloramphenicol resistance as described in Example 5. A control dephosphorylation reaction using calf-alkaline phosphatased-pAC80 was performed since the inserted DNA did not generate a selectable phenotype. Tetracycline- and chloramphenicol-resistant transformants were screened after plasmid miniprep purification using the Fermentas GeneJet kit.
- Recombinant vectors were screened by restriction digestion using BamHI and HindIII and confirmed clones were used in later experiments. Additionally, all recombinant vectors used for transformation experiments were sequence verified. The final construct is shown in FIG. 6 and was designated pCOSMTI-12.
- Methyltransferase genes are also cloned into a broad-host range vector to expand the range of hosts from which plasmid DNA can be retrieved and electrotransformed and mobilized into Clostridial hosts.
- a broad-host range vector for cloning the MTI-1 polynucleotide into the broad-host range plasmid pBBR1 an EcoRI digestion is performed on pAC80 to release the MTI-1 “cassette” containing Ppta-ack operably linked to the MTI-1 polynucleotide and ligated to EcoRI-digested pBBR1 using T4 DNA ligase (Fermentas), which is dephosphorylated with calf-alkaline phosphatase using 1 unit of phosphatase for 10 minutes.
- T4 DNA ligase Fermentas
- the ligation proceeds for 10 minutes using rapid DNA ligase and the ligation mixture is purified using the Qiaex kit.
- One microliter of the ligation mixture is used to transform E. coli DH10B with selection for chloramphenicol resistance.
- Recombinant plasmids are identified after replica patching onto 2 ⁇ YT agar medium containing chloramphenicol or thiamphenicol (25 ⁇ g per ml of agar) and kanamycin sulfate (50 ⁇ g per ml agar).
- E. coli strains which display a thiamphenicol-resistant, kanamycin-sensitive phenotype are purified and further characterized by restriction digestion and sequencing for confirmation.
- One such plasmid, pBBRMTI-1 can be used in transformation and conjugation experiments.
- a similar procedure is used except the methyltransferase cassette is released from pAC82 using PstI and cloned into a unique PstI site on a modified pBBR-1.
- the PstI site is made unique by previously releasing a 1.240 kb PstI fragment containing the entire kanamycin resistance gene and surrounding sequences and religating the large 4.060 kb fragment to form ⁇ KnpBBR1.
- Plasmid ⁇ KnpBBR1 is digested with PstI and dephosphorylated with calf alkaline phosphatase and ligated to a 1.975 kb PstI fragment containing the MTI-2 cassette including the Pptaack from pAC82. The ligation proceeds for 10 minutes using rapid DNA ligase and is purified using the Qiaex kit. Transformation of E. coli DH10B cells is performed using 1 ⁇ l ligation mixture with selection on 2 ⁇ YT agar medium containing thiamphenicol at 25 ⁇ g/ml 2 ⁇ YT agar medium. Thiamphenicol-resistant strains are screened by restriction digestion using PstI. After restriction digestion screening of ten colonies and sequence confirmation across the MTI-2 gene six such plasmids are isolated and designated pBBRMTI-2. One such plasmid is used in transformations and conjugations.
- a BamHI digest of pCOSMTI-12 is performed to release a 3.657 kb fragment.
- the fragment is blunted using T4 DNA polymerase (Fermentas) according to the manufacturer's instructions.
- Plasmid pBBR1 is digested with SmaI and dephosphorylated with calf-alkaline phosphatase as described above.
- the 3.657 kb Type I methyltransferase gene cassette is gel purified and ligated to SmaI-digested pBBR1 using rapid T4 DNA ligase.
- Ligation mixtures are purified and transformed into electrocompetent E. coli DH10B cells and selected on 2 ⁇ YT agar plates containing thiamphenicol (25 ⁇ g per ml 2 ⁇ YT agar).
- Candidate recombinants are replica patched onto 2 ⁇ YT medium containing kanamycin at 50 ⁇ g per ml agar and incubated overnight at 37° C. Strains that displayed a Thiamphenicol-positive, kanamycin-sensitive phenotype are further analyzed by restriction digestion and sequencing.
- Putative recombinants are digested with BamHI and PstI and analyzed on a 0.8% agarose gel (1 ⁇ TAE buffer). Four such recombinants containing the entire 3.657 kb methylatransferase cassette are confirmed and designated pBBRMTI-12 and will be used in transformation and conjugation experiments.
- Vector pACR-1 is an E. coli - Clostridium shuttle vector containing cross-functional replicons and antibiotic markers.
- Vector pUC19 was digested with SalI and dephosphorylated with calf-alkaline phosphatase as described in previous Examples. After enzymatic treatment the plasmid DNA was precipitated with isopropanol (0.6-1.0 volume) and placed at ⁇ 20° C. for 1 hour. DNA was pelleted at 12,000 ⁇ g for 10 minutes in a minicentrifuge and washed with ice cold 70% ethanol and dried. The DNA pellet was resuspended in 30 ⁇ l of Tris buffer pH 8.0.
- a 1.730 kb SalI-PstI fragment contained on a pMB1 replicating vector (pGEM T easy, Promega, Madison Wis.) containing replicon repL and an erythromycin resistance gene (an origin of replication and antibiotic resistance gene that both function in Clostridia ) originally derived from pE194 (Weisblum et al., 1979, Journal of Bacteriology , Plasmid copy control: Isolation and characterization of high-copy-number mutants of plasmid pE194, 137:635-643) was ligated to pUC19 using rapid T4 DNA ligase. After transformation and selection, vectors were screened and confirmed by restriction analysis and sequencing junction regions. This general E.
- coli - Clostridium shuttle vector was designated pACR1 ( FIG. 7A ).
- Alternative antibiotic selection markers were generated by cloning separately tetracycline (originally derived from pACYC184), chloramphenicol (originally derived from pACYC184) and kanamycin (originally derived from Tn5) resistance genes expressed from a clostridial promoter (Psadh), into unique sites located in the multiple cloning region contained in the vector. After purification, ligation mixtures were transformed into DH10B electrocompetent E. coli with selection for dual antibiotic resistance.
- Vector pACC-1 is an E. coli - Clostridium conjugative vector containing mobilization and origin of transfer genes from RP4 and cross-functional antibiotic selection markers expressed from a Clostridial promoter.
- Plasmid pARO190 (Parke D, 1990, Gene , Construction of mobilizable vectors derived from plasmids RP4, pUC18 and pUC19 93(1): 135-137) was used as the starting vector since it contains the basis for mobilization region and origin of transfer (BOM) along with a convenient multiple cloning site.
- Plasmid pARO190 was digested with SalI and dephosphorylated with rapid calf alkaline phosphatase for 10 minutes at 37° C.
- the vector was purified by Qiaex kit and resuspended in 30 ⁇ l Tris buffer pH 8.0. One ⁇ l of this ( ⁇ 50 ⁇ g) was used in dephosphorylation control tests. Additionally, pARO190 has the lacZ ⁇ complementation fragment so blue/white screening was used in the initial cloning step. The 1.730 kb fragment containing repL and the erythromycin resistance gene (Em) was released with SalI, gel purified and ligated to Sail-digested dephosphorylated pARO190 using T4 DNA ligase for 10 minutes at room temperature.
- Em erythromycin resistance gene
- the ligation mixture was resuspended in 30 ⁇ l of Tris buffer pH 8.0.
- One ⁇ l of ligation mixture was electroporated into DH10B electrocompetent cells and plated on 2 ⁇ YT agar containing ampicillin at a concentration of 100 ⁇ g per ml agar medium.
- the blue-white indicator X-gal (5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside) was added to the 2 ⁇ YT agar at a final concentration of 20 ⁇ g per ml to screen for plasmids containing inserts.
- antibiotic resistance markers were ligated into pACC-1 in the multiple cloning site as described in Example 6.
- the antibiotic resistance markers were expressed from a strong clostridial promoter, Psadh, and were cloned into either the EcoRI, BamHI, or XbaI sites.
- the antibiotic resistance marker cassettes were released using the appropriate enzyme from pGEM T easy-cloned PCR products, gel purified using a Qiaex kit and ligated to dephosphorylated pACC-1 using rapid T4 DNA ligase.
- FIG. 8B Vector pACC-1 containing the TcR gene expressed from a clostridial promoter is shown in FIG. 8B .
- the 1.730 kb repL-Em cassette was deleted from the appropriate pACC-1-based vector using SalI and religated using T4 DNA ligase. These vectors were also modified to contain homologous DNA for integration into the host chromosome.
- Vector constructs pCOSMTI-1, pCOSMTI-2, pCOSMTI-12 were transformed into E. coli host strains with varying restriction-modification systems.
- Genotypically R/M variable, commercial strains contain one or more mutations in the four R/M systems known to exist in E. coli.
- E. coli DH10B (Life Technologies, Carlsbad, Calif.) contains mutations in the mcrABmrr and hsd systems.
- E. coli BL21 contains mutations in the dcm system.
- E. coli DH5 ⁇ -e is positive for all systems except the hsdB system.
- E. coli ER2275 has a similar genotype as DH10B with regard to its restriction-modification systems.
- E. coli strain GM2163 is R/M negative.
- Vectors pCOSMTI-1, pCOSMTI-2, pCOSMTI-12, and pCOSMTII-1 were separately electrotransformed into E. coli BL21, DH10B, DH5 ⁇ -e, GM2163 and ER2275 using 0.1 cm gap cuvettes maintained at 4° C. and 20 ⁇ l of cells with selection on 2 ⁇ YT agar plates containing chloramphenicol at 25 ⁇ g per ml of agar.
- the E. coli host strains BL21, DH10B, DH5 ⁇ -e, GM2163 and ER2275 containing the methylation vectors, pCOSMTI-1, pCOSMTI-2, pCOSMTI-12, pMTII-1 were made electrocompetent according to the method described in Sambrook et al (In: Molecular cloning: a laboratory manual, 1987. J. Sambrook, E. F. Fritsch, T. Maniatis. Sambrook, J.). Vectors pACR-1 and the pACC-1 series are compatible with vectors pCOSMTI-1, pCOSMTI-2, pCOSMTI-12, pMTII-1 and can co-reside in the same cell with appropriate antibiotic selection ( FIG.
- FIG. 9 shows co-residency of two such co-resident vector E. coli strains containing pCOSMTI-12 and pACR-1 and pCOSMTI-12 and pACC-1ET.
- a 1.2% Tris-Borate-EDTA (TBE, pH 8.0) gel was run to resolve vectors after restriction digestion with BamHI or HindIII.
- E. coli DH10B was transformed with pACR-1 only, with pACR-1 in a host containing pCOSMTI-12, with pACC-1 in a host already containing pMTI-1 and with a host already containing pCOSMTI-12.
- the 1.942 kb band is much less bright than pACR-1, since the methylation vector is approximately 1/40 th the copy number of pACR-1.
- Plasmid DNA digested from E. coli co-residing pACC-1 and pCOSMTI-1 was digested with BamHI and the expected 1.942 kb band containing the Ppta-MTI-1 cassette was observed along with the larger remaining parts of the vectors ( FIG. 9 , lane 3). Digesting plasmid DNA from the E.
- Transformation experiments were performed in order to determine the effects of methylated DNA on gene transfer and stable replication in C. autoethanogenum and other solventogenic Clostridia .
- Plasmid DNA was quantified and desalted using 100 kDa UF filters (Millipore, Bedford Mass.) and a 40-fold volume of 10 mM Tris buffer pH 8.0.
- For each electrotransformation 1-3 ⁇ g of DNA was used and transferred to an ice-cold 0.2 cm gap cuvette containing 50 ⁇ l of electrocompetent C. autoethanogenum, C. ragsdalei and C. coskatii previously frozen at ⁇ 80° C. according to the method described by Leang et al. (Leang et al.
- Electrocompetent cells were prepared from single colony isolates grown on fermentation medium (Tables 1 and 2) containing 0.5% fructose and 10 g per liter yeast extract. Cells were initially grown in 5 ml of fermentation medium in anaerobic Balch tubes with a headspace of N 2 CO 2 H 2 (80:15:5) for 48 hours and transferred three times in 150 ml serum bottles containing 20 ml fermentation medium containing 40 mM DL-threonine with a consistent gas phase. Cells were harvested anaerobically at early and mid-log phase of growth (OD 600 nm 0.3 to 0.7) at 3225 ⁇ g for 20 minutes, washed with SMP buffer 2 times and concentrated 100-fold before freezing.
- Competent cells were rapidly frozen in an alcohol bath maintained at ⁇ 80° C.
- For electrotransfer into competent Clostridial cells 1 ⁇ g of methylated DNA was added and mixed. Electroporation was carried out in a Bio-rad Excel electroporator (Bio-rad, Hercules Calif.) set to 25 ⁇ F, 600 ⁇ , 1.5-2.5 kV. After electroshock, cells were immediately resuspended in warmed fermentation medium and transferred to anaerobic Balch tubes containing 4 ml fermentation medium for recovery overnight. The next day, after some perceptible change in OD was observed, cells were pelleted at 10,000 ⁇ g in a microfuge and plated on fermentation medium agar supplemented with 0.5% fructose and the appropriate antibiotic for selection of transformants. Control experiments using unmethylated DNA were performed alongside experiments using DNA methylated with the two Clostridial Type I methylation vectors and a control Type II methyltransferase expression vector, pCOSMTII-1.
- E. coli XL1-Blue strains were electrotransformed with the E. coli - Clostridium shuttle vector pACR1 and either pCOSMTI-1, pCOSMTI-2, pCOSMTI-12, or pCOSMTII-1 to generate a series of co-residing plasmid vector strains. Selection for co-residing plasmids in E. coli was done on LB agar medium (Sambrook et al. 1989) containing erythromycin at 50 ⁇ g/ml and tetracycline at 10 ⁇ g/ml. After overnight growth at 37° C.
- Table 3 shows the results of gene transfer experiments using plasmids pCOSMTI-1, pCOSMTI-2, pCOSMTII-I and pACR1.
- pACR1 alone showed a transformation frequency of about 135 CFU/ ⁇ g.
- Type I methyltransferase MTI-1 was used to methylate pACR1 a slightly higher number of CFU/ ⁇ g was observed (Table 3).
- Using DNA methylated by MTI-2 showed an almost 10-fold increase in transformation frequency (Table 3).
- the Type II methyltransferase MTII-1 didn't show any difference in transformation frequency when compared to the unmethylated DNA control vector, pACR1.
- Plasmid CFU/plate DNA( ⁇ g) a Frequency b pACR1 325 3 135 CFU/ ⁇ g pCOSMTI-1 384 3 160 CFU/ ⁇ g pCOSMTI-2 3201 3 1333 CFU/ ⁇ g pCOSMTII-1 285 3 118 CFU/ ⁇ g ND — 0 0 a represents the total amount of shuttle vector and methylating vector DNA; b represents the total CFU generated from transfer and replication of shuttle vector only.
- E. coli S-17 contains chromosomal functions that assist in the conjugal transfer of DNA in a bi-parental mating. This has been shown to improve conjugal transfer up to 5-10 fold versus using a triparental mating scheme. In those cases where a more variable methylation pattern was desired, tri-parental matings were performed with an E. coli helper strain, E.
- C. autoethanogenum was grown in anaerobic fermentation medium as described in Example 10. Before the filter mating procedure, the culture was transferred three times at early log phase (OD 600 nm 0.3) before harvesting and mixing with E. coli . For conjugations, E. coli was grown in LB medium with maintenance levels of ampicillin and tetracycline (10 ⁇ g per ml ampicillin and 1 ⁇ g per ml tetracycline) to an OD 600nm of 0.5 .
- Clostridia were grown to an OD 600nm of between 0.3 and 0.7 when mixed with an equal volume of E. coli based on cell counts. If the optical densities were slightly different from previously established cell counts relating to cells/ml of broth the volumes were adjusted accordingly. Mixtures of cells were pelleted by centrifugation at 1000 ⁇ g and resuspended in liquid medium at an equivalent OD of 5 and plated on previously sterilized 0.22 ⁇ M filters (Millipore) on fermentation medium agar or RCM (Difco, Becton Dikinson, Franklin Lakes, N.J.) agar. Matings were allowed to proceed for 24 hours at 37° C.
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Description
| TABLE 1 |
| Fermentation Medium Compositions |
| Components | Amount per liter | ||
| Mineral solution, See Table 2(a) | 25 ml | ||
| Trace metal solution, See Table 2(b) | 10 ml | ||
| Vitamins solution, See Table 2(c) | 10 ml | ||
| Yeast Extract | 0.5 g | ||
| Adjust pH with NaOH | 5.8 | ||
| Reducing agent, See Table 2(d) | 2.5 ml | ||
| TABLE 2(a) |
| Mineral Solution |
| Components | Concentration (g/L) | ||
| NaCl | 80 | ||
| NH4Cl | 100 | ||
| KCl | 10 | ||
| KH2PO4 | 10 | ||
| MgSO4•7H2O | 20 | ||
| CaCl2•2H2O | 4 | ||
| TABLE 2(b) |
| Trace Metals Solution |
| Components | Concentration (g/L) | ||
| Nitrilotriacetic acid | 2.0 |
| Adjust the pH to 6.0 with KOH |
| MnSO4•H2O | 1.0 | ||
| Fe(NH4)2(SO4)2•6H2O | 0.8 | ||
| CoCl2•6H2O | 0.2 | ||
| ZnSO4•7H2O | 1.0 | ||
| NiCl2•6H2O | 0.2 | ||
| Na2MoO4•2H2O | 0.02 | ||
| Na2SeO4 | 0.1 | ||
| Na2WO4 | 0.2 | ||
| TABLE 2(c) |
| Vitamin Solution |
| Components | Concentration (mg/L) | ||
| Pyridoxine•HCl | 10 | ||
| Thiamine•HCl | 5 | ||
| Riboflavin | 5 | ||
| Calcium Pantothenate | 5 | ||
| Thioctic acid | 5 | ||
| p-Aminobenzoic acid | 5 | ||
| Nicotinic acid | 5 | ||
| Vitamin B12 | 5 | ||
| Mercaptoethanesulfonic acid | 5 | ||
| |
2 | ||
| |
2 | ||
| TABLE 2(d) |
| Reducing Agent |
| Components | Concentration (g/L) | ||
| Cysteine (free base) | 40 | ||
| Na2S•9H2O | 40 | ||
| Plasmid | CFU/plate | DNA(μg)a | Frequencyb |
| pACR1 | 325 | 3 | 135 CFU/μg |
| pCOSMTI-1 | 384 | 3 | 160 CFU/μg |
| pCOSMTI-2 | 3201 | 3 | 1333 CFU/μg |
| pCOSMTII-1 | 285 | 3 | 118 CFU/μg |
| ND | — | 0 | 0 |
| arepresents the total amount of shuttle vector and methylating vector DNA; | |||
| brepresents the total CFU generated from transfer and replication of shuttle vector only. | |||
| SEQ ID NO: 1: Polynucleotide sequence of MtaseI-1 | |
| ATGAATACACAGGAAATAGTAAGCAAACTTTGGAACCTTTGTAACGTACTAAGAGA | |
| TGATGGAATAACTTATCATCAATATGTAACAGAATTAACATATATTCTTTTCTTAAA | |
| GATGGCAAAGGAAACAGGTACAGAGGATAAATTGCCAGAAGGTTATAGATGGGAT | |
| GATTTAAAAGTTTATAGAGGAATGGAACTTAAGAAATTTTATAATAAATTATTAAAT | |
| TATCTTGGAGAAAAGACTACTGGGATAGTGCAAAAAATATATCAGGGATCTGCAAC | |
| AAATATAGAAGAACCAAAAAATCTAGAAAAAATAATTAAAACTATAGATGGATTAG | |
| ATTGGTATTCAGCAAAAGAAGAAGGACTTGGAAACTTATATGAAGGATTACTTGAA | |
| AAAAATGCATCTGAGAAAAAATCTGGTGCAGGACAATACTTTACTCCAAGAGTATT | |
| AATTAATGTTATGGTGGAACTTATTGATCCAAAACCAGGTGAAAAATGCAATGACCC | |
| TGCAGCAGGAACCTTTGGATTTATGATTGCTGCAGATCGTTACATGAAACAGAAAAC | |
| AGACAACTATTTTGATTTAGGTACAGAACTTCAAGAGTTTCAGAGAACTAAGGCTTT | |
| TTCTGGCTGTGAATTAGTTCACGAAACACATAGATTAGCCCTTATGAATGCTATGCT | |
| TCATGATATAGAAGGAAACATAATCCTCGGAGATACTTTAACAAATACAGGAAAGC | |
| AGATGAAAGACTTAAATGTTGTGCTTTCAAACCCTCCATTTGGAACTAAAAGAGGTG | |
| GTGAAAGAGCAACAAGAGATGATTTGACTTACATGACTTCAAATAAACAATTAAAC | |
| TTCTTGCAGCACATATATAGAAGTTTAAAAGCAGATGGAAAAGCAAGAGCAGCTGT | |
| GGTATTGCCAGATAATGTACTATTTGATCATAATGATGGAGCGAAGATTCGTGCGGA | |
| TTTAATGGATAAATGTAATCTACATACAATATTACGGTTACCTACTGGTATTTTCTAT | |
| GCTAAAGGAGTTAAAACAAATGTGCTTTTCTTTACTAGAGGTACTAGTGATAAAGAC | |
| AATACTAAAGAAGTTTGGATATATGATTTGCGTACCAATATGCCTAGCTTTGGAAAG | |
| ACAAATCCTTTAAAGAAAGAGCATTTTGAAGACTTTATAAAGGCTTATACTTCTGAG | |
| GATAGAACAAAGGTGAAAGATGAACGTTTTTCGGTATTTACTAGAGAAGAAATAAA | |
| AGAGAAAAATGATAACCTTGACCTAGGTTTAATTCGTGATGAAAGTGTATTAGACTA | |
| TGAAGATCTACAAGATCCAATTGAAAGTGGTGAAGAAATAACTTCACAACTTGAAG | |
| AGGCAATGGATTTAATCCAAACTGTTGTAAAGAAACTAAAGATTTTAGGCGGTGAC | |
| AGGTAA | |
| SEQ ID NO: 2: Amino acid sequence of MtaseI-1. | |
| M N T Q E I V S K L W N L C N V L R D D G I T Y H Q Y V T E L T Y I | |
| L F L K M A K E T G T E D K L P E G Y R W D D L K V Y R G M E L K | |
| K F Y N K L L N Y L G E K T T G I V Q K I Y Q G S A T N I E E P K N | |
| L E K I I K T I D G L D W Y S A K E E G L G N L Y E G L L E K N A S | |
| E K K S G A G Q Y F T P R V L I N V M V E L I D P K P G E K C N D P | |
| A A G T F G F M I A A D R Y M K Q K T D N Y F D L G T E L Q E F Q | |
| R T K A F S G C E L V H E T H R L A L M N A M L H D I E G N I I L G | |
| D T L T N T G K Q M K D L N V V L S N P P F G T K R G G E R A T R | |
| D D L T Y M T S N K Q L N F L Q H I Y R S L K A D G K A R A A V V | |
| L P D N V L F D H N D G A K I R A D L M D K C N L H T I L R L P T G | |
| I F Y A K G V K T N V L F F T R G T S D K D N T K E V W I Y D L R T | |
| N M P S F G K T N P L K K E H F E D F I K A Y T S E D R T K V K D E | |
| R F S V F T R E E I K E K N D N L D L G L I R D E S V L D Y E D L Q | |
| D P I E S G E E I T S Q L E E A M D L I Q T V V K K L K I L G G D R | |
| SEQ ID NO: 3: Polynucleotide sequence of Mtase I-2. | |
| ATGTCAATAACAAACGTAGTAAAATCAGTACAAGATATAATGCGCCAGGATGCAGG | |
| GGTAGATGGAGATGCTCAAAGAATATCTCAACTAGTTTGGATGATATTTTTAAAGGT | |
| ATTTGATGCAAAAGAAGAGGAATGGGAATTAGAGTATGATGATTATACACCTATTA | |
| TTCCAGAAGAATTGAGATGGAGCAACTGGGCTCAAGATGATGAAGGAATTACAGGC | |
| GATGAGCTTTTAGACTTTGTAAACAATAAATTATTCAAAGGTTTAAAGGAAATGGAA | |
| GTAGATGAGAATAGTGATGCTAAAGCTTTATTAGTTAAATCTGTATTTGAAGATTCC | |
| TATAATTATATGAAATCAGGAGCTTTAATGAGGCAGGTAATAAATAAGTTAAATGA | |
| AATAGATTTTACAGCAGGTGAAGACAGACATTTATTTAATGATATATATGAAAATAT | |
| ATTAAAAGATCTTCAAAGTGCAGGCAATGCAGGAGAATTCTATACACCAAGACCTG | |
| TTACACAATTTATAATAGATATGCTAAGTCCAAAGCTTGGTGAAAAAGTAGCTGACT | |
| TTGCTTGTGGTACCGGTGGATTTTTAACATGTGCCATAGAAAACTTAAAAAAACAGG | |
| AAACCAAAGTTGAAGATTTAAAAATATTAGGTGAAACCATAATGGGTGTAGAAAAG | |
| AAACCGCTTCCTCACATGCTTGCTACAACTAACCTGATACTTCATGATATTGATGTGC | |
| CAAACATAAAACATGATAATTCTTTGATGAAGAATGTAAGAGATTTAAAGCCTTCAG | |
| AATATGTGGATGTAATAGCAATGAATCCTCCTTTTGGCGGAATTGAAGAAGATATGG | |
| TACTAACTAATTTCCCTCAGCAGTTTCAAACAAAAGAAACAGCAGATTTATTTATGA | |
| CTCTTATAATGTATAGATTAAGTGAAAAAGGAAGAGCGGGAGTAGTACTTCCAGAT | |
| GGATTTTTATTTGGTGAAGGTGTAAAGACTCATATAAAAGAAAAACTTTTAAATGAA | |
| TTTAACCTTCATACTATAGTAAGAATGCCTAATGGAGTATTTGCCCCATATACGGGA | |
| ATAAATACAAACCTTTTATTCTTTGAAAAAGGTAAGCCAACAGAAGAAGTTTGGTTC | |
| TTTGAACATCCACTTCCTGAAGGATATAAAAATTATACTAAAACCAAACCAATAAGA | |
| TATGAAGAATTTGAACTGGAGAAGAAGTGGTGGAATAACAGAGAAGAAAATGAGT | |
| ATGCGTGGAAGGTTTCAGTAGAGGACATTAAAAATAGAAATTATAATTTAGATTATA | |
| AAAATCCTAATAAGGAAGAAGAAGATTTAGGAGATCCAAAGGCATTATTAAAAAAA | |
| TATCATGAAGCTGCTGCTGATGTAGATAAATTGCAAGATTCTTTGATAGATGAATTA | |
| AAGAAGATTTTAGAAGGGACATCAAAATAG | |
| SEQ ID NO: 4: Amino acid sequence of Mtase I-2. | |
| M S I T N V V K S V Q D I M R Q D A G V D G D A Q R I S Q L V W M | |
| I F L K V F D A K E E E W E L E Y D D Y T P I I P E E L R W S N W A | |
| Q D D E G I T G D E L L D F V N N K L F K G L K E M E V D E N S D | |
| A K A L L V K S V F E D S Y N Y M K S G A L M R Q V I N K L N E I | |
| D F T A G E D R H L F N D I Y E N I L K D L Q S A G N A G E F Y T P | |
| R P V T Q F I I D M L S P K L G E K V A D F A C G T G G F L T C A I | |
| E N L K K Q E T K V E D L K I L G E T I M G V E K K P L P H M L A T | |
| T N L I L H D I D V P N I K H D N S L M K N V R D L K P S E Y V D V | |
| I A M N P P F G G I E E D M V L T N F P Q Q F Q T K E T A D L F M T | |
| L I M Y R L S E K G R A G V V L P D G F L F G E G V K T H I K E K L | |
| L N E F N L H T I V R M P N G V F A P Y T G I N T N L L F F E K G K | |
| P T E E V W F F E H P L P E G Y K N Y T K T K P I R Y E E F E L E K | |
| K W W N N R E E N E Y A W K V S V E D I K N R N Y N L D Y K N P | |
| N K E E E D L G D P K A L L K K Y H E A A A D V D K L Q D S L I D | |
| E L K K I L E G T S K | |
| SEQ ID NO: 5: Pptaack + Mtase I-1 | |
| TGATTGATTATTTATTTTAAAATGCCTAAGTGAAATATATACATATTATAACAATAA | |
| AATAAGTATTAGTGTAGGATTTTTAAATAGAGTATCTATTTTCAGATTAAATTTTTGA | |
| TTATTTGATTTACATTATATAATATTGAGTAAAGTATTGACTAGCAAAATTTTTTGAT | |
| ACTTTAATTTGTGAAATTTCTTATCAAAAGTTATATTTTTGAATAATTTTTATTGAAA | |
| AATACAACTAAAAAGGATTATAGTATAAGTGTGTGTAATTTTGTGTTAAATTTAAAG | |
| GGAGGAAAATGAATACACAGGAAATAGTAAGCAAACTTTGGAACCTTTGTAACGTA | |
| CTAAGAGATGATGGAATAACTTATCATCAATATGTAACAGAATTAACATATATTCTT | |
| TTCTTAAAGATGGCAAAGGAAACAGGTACAGAGGATAAATTGCCAGAAGGTTATAG | |
| ATGGGATGATTTAAAAGTTTATAGAGGAATGGAACTTAAGAAATTTTATAATAAATT | |
| ATTAAATTATCTTGGAGAAAAGACTACTGGGATAGTGCAAAAAATATATCAGGGAT | |
| CTGCAACAAATATAGAAGAACCAAAAAATCTAGAAAAAATAATTAAAACTATAGAT | |
| GGATTAGATTGGTATTCAGCAAAAGAAGAAGGACTTGGAAACTTATATGAAGGATT | |
| ACTTGAAAAAAATGCATCTGAGAAAAAATCTGGTGCAGGACAATACTTTACTCCAA | |
| GAGTATTAATTAATGTTATGGTGGAACTTATTGATCCAAAACCAGGTGAAAAATGCA | |
| ATGACCCTGCAGCAGGAACCTTTGGATTTATGATTGCTGCAGATCGTTACATGAAAC | |
| AGAAAACAGACAACTATTTTGATTTAGGTACAGAACTTCAAGAGTTTCAGAGAACT | |
| AAGGCTTTTTCTGGCTGTGAATTAGTTCACGAAACACATAGATTAGCCCTTATGAAT | |
| GCTATGCTTCATGATATAGAAGGAAACATAATCCTCGGAGATACTTTAACAAATACA | |
| GGAAAGCAGATGAAAGACTTAAATGTTGTGCTTTCAAACCCTCCATTTGGAACTAAA | |
| AGAGGTGGTGAAAGAGCAACAAGAGATGATTTGACTTACATGACTTCAAATAAACA | |
| ATTAAACTTCTTGCAGCACATATATAGAAGTTTAAAAGCAGATGGAAAAGCAAGAG | |
| CAGCTGTGGTATTGCCAGATAATGTACTATTTGATCATAATGATGGAGCGAAGATTC | |
| GTGCGGATTTAATGGATAAATGTAATCTACATACAATATTACGGTTACCTACTGGTA | |
| TTTTCTATGCTAAAGGAGTTAAAACAAATGTGCTTTTCTTTACTAGAGGTACTAGTG | |
| ATAAAGACAATACTAAAGAAGTTTGGATATATGATTTGCGTACCAATATGCCTAGCT | |
| TTGGAAAGACAAATCCTTTAAAGAAAGAGCATTTTGAAGACTTTATAAAGGCTTATA | |
| CTTCTGAGGATAGAACAAAGGTGAAAGATGAACGTTTTTCGGTATTTACTAGAGAA | |
| GAAATAAAAGAGAAAAATGATAACCTTGACCTAGGTTTAATTCGTGATGAAAGTGT | |
| ATTAGACTATGAAGATCTACAAGATCCAATTGAAAGTGGTGAAGAAATAACTTCAC | |
| AACTTGAAGAGGCAATGGATTTAATCCAAACTGTTGTAAAGAAACTAAAGATTTTA | |
| GGCGGTGACAGGTAA | |
| SEQ ID NO: 6: Pptaack + MtaseI-2 | |
| GATCCTGATTGATTATTTATTTTAAAATGCCTAAGTGAAATATATACATATTATAACA | |
| ATAAAATAAGTATTAGTGTAGGATTTTTAAATAGAGTATCTATTTTCAGATTAAATTT | |
| TTGATTATTTGATTTACATTATATAATATTGAGTAAAGTATTGACTAGCAAAATTTTT | |
| TGATACTTTAATTTGTGAAATTTCTTATCAAAAGTTATATTTTTGAATAATTTTTATTG | |
| AAAAATACAACTAAAAAGGATTATAGTATAAGTGTGTGTAATTTTGTGTTAAATTTA | |
| AAGGGAGGAAAATGTCAATAACAAACGTAGTAAAATCAGTACAAGATATAATGCGC | |
| CAGGATGCAGGGGTAGATGGAGATGCTCAAAGAATATCTCAACTAGTTTGGATGAT | |
| ATTTTTAAAGGTATTTGATGCAAAAGAAGAGGAATGGGAATTAGAGTATGATGATT | |
| ATACACCTATTATTCCAGAAGAATTGAGATGGAGCAACTGGGCTCAAGATGATGAA | |
| GGAATTACAGGCGATGAGCTTTTAGACTTTGTAAACAATAAATTATTCAAAGGTTTA | |
| AAGGAAATGGAAGTAGATGAGAATAGTGATGCTAAAGCTTTATTAGTTAAATCTGT | |
| ATTTGAAGATTCCTATAATTATATGAAATCAGGAGCTTTAATGAGGCAGGTAATAAA | |
| TAAGTTAAATGAAATAGATTTTACAGCAGGTGAAGACAGACATTTATTTAATGATAT | |
| ATATGAAAATATATTAAAAGATCTTCAAAGTGCAGGCAATGCAGGAGAATTCTATA | |
| CACCAAGACCTGTTACACAATTTATAATAGATATGCTAAGTCCAAAGCTTGGTGAAA | |
| AAGTAGCTGACTTTGCTTGTGGTACCGGTGGATTTTTAACATGTGCCATAGAAAACT | |
| TAAAAAAACAGGAAACCAAAGTTGAAGATTTAAAAATATTAGGTGAAACCATAATG | |
| GGTGTAGAAAAGAAACCGCTTCCTCACATGCTTGCTACAACTAACCTGATACTTCAT | |
| GATATTGATGTGCCAAACATAAAACATGATAATTCTTTGATGAAGAATGTAAGAGAT | |
| TTAAAGCCTTCAGAATATGTGGATGTAATAGCAATGAATCCTCCTTTTGGCGGAATT | |
| GAAGAAGATATGGTACTAACTAATTTCCCTCAGCAGTTTCAAACAAAAGAAACAGC | |
| AGATTTATTTATGACTCTTATAATGTATAGATTAAGTGAAAAAGGAAGAGCGGGAGT | |
| AGTACTTCCAGATGGATTTTTATTTGGTGAAGGTGTAAAGACTCATATAAAAGAAAA | |
| ACTTTTAAATGAATTTAACCTTCATACTATAGTAAGAATGCCTAATGGAGTATTTGC | |
| CCCATATACGGGAATAAATACAAACCTTTTATTCTTTGAAAAAGGTAAGCCAACAGA | |
| AGAAGTTTGGTTCTTTGAACATCCACTTCCTGAAGGATATAAAAATTATACTAAAAC | |
| CAAACCAATAAGATATGAAGAATTTGAACTGGAGAAGAAGTGGTGGAATAACAGA | |
| GAAGAAAATGAGTATGCGTGGAAGGTTTCAGTAGAGGACATTAAAAATAGAAATTA | |
| TAATTTAGATTATAAAAATCCTAATAAGGAAGAAGAAGATTTAGGAGATCCAAAGG | |
| CATTATTAAAAAAATATCATGAAGCTGCTGCTGATGTAGATAAATTGCAAGATTCTT | |
| TGATAGATGAATTAAAGAAGATTTTAGAAGGGACATCAAAATAG | |
| SEQ ID NO: 7: Pptaack-MTI-12 | |
| TGATTGATTATTTATTTTAAAATGCCTAAGTGAAATATATACATATTATAACAATAA | |
| AATAAGTATTAGTGTAGGATTTTTAAATAGAGTATCTATTTTCAGATTAAATTTTTGA | |
| TTATTTGATTTACATTATATAATATTGAGTAAAGTATTGACTAGCAAAATTTTTTGAT | |
| ACTTTAATTTGTGAAATTTCTTATCAAAAGTTATATTTTTGAATAATTTTTATTGAAA | |
| AATACAACTAAAAAGGATTATAGTATAAGTGTGTGTAATTTTGTGTTAAATTTAAAG | |
| GGAGGAAAATGAATACACAGGAAATAGTAAGCAAACTTTGGAACCTTTGTAACGTA | |
| CTAAGAGATGATGGAATAACTTATCATCAATATGTAACAGAATTAACATATATTCTT | |
| TTCTTAAAGATGGCAAAGGAAACAGGTACAGAGGATAAATTGCCAGAAGGTTATAG | |
| ATGGGATGATTTAAAAGTTTATAGAGGAATGGAACTTAAGAAATTTTATAATAAATT | |
| ATTAAATTATCTTGGAGAAAAGACTACTGGGATAGTGCAAAAAATATATCAGGGAT | |
| CTGCAACAAATATAGAAGAACCAAAAAATCTAGAAAAAATAATTAAAACTATAGAT | |
| GGATTAGATTGGTATTCAGCAAAAGAAGAAGGACTTGGAAACTTATATGAAGGATT | |
| ACTTGAAAAAAATGCATCTGAGAAAAAATCTGGTGCAGGACAATACTTTACTCCAA | |
| GAGTATTAATTAATGTTATGGTGGAACTTATTGATCCAAAACCAGGTGAAAAATGCA | |
| ATGACCCTGCAGCAGGAACCTTTGGATTTATGATTGCTGCAGATCGTTACATGAAAC | |
| AGAAAACAGACAACTATTTTGATTTAGGTACAGAACTTCAAGAGTTTCAGAGAACT | |
| AAGGCTTTTTCTGGCTGTGAATTAGTTCACGAAACACATAGATTAGCCCTTATGAAT | |
| GCTATGCTTCATGATATAGAAGGAAACATAATCCTCGGAGATACTTTAACAAATACA | |
| GGAAAGCAGATGAAAGACTTAAATGTTGTGCTTTCAAACCCTCCATTTGGAACTAAA | |
| AGAGGTGGTGAAAGAGCAACAAGAGATGATTTGACTTACATGACTTCAAATAAACA | |
| ATTAAACTTCTTGCAGCACATATATAGAAGTTTAAAAGCAGATGGAAAAGCAAGAG | |
| CAGCTGTGGTATTGCCAGATAATGTACTATTTGATCATAATGATGGAGCGAAGATTC | |
| GTGCGGATTTAATGGATAAATGTAATCTACATACAATATTACGGTTACCTACTGGTA | |
| TTTTCTATGCTAAAGGAGTTAAAACAAATGTGCTTTTCTTTACTAGAGGTACTAGTG | |
| ATAAAGACAATACTAAAGAAGTTTGGATATATGATTTGCGTACCAATATGCCTAGCT | |
| TTGGAAAGACAAATCCTTTAAAGAAAGAGCATTTTGAAGACTTTATAAAGGCTTATA | |
| CTTCTGAGGATAGAACAAAGGTGAAAGATGAACGTTTTTCGGTATTTACTAGAGAA | |
| GAAATAAAAGAGAAAAATGATAACCTTGACCTAGGTTTAATTCGTGATGAAAGTGT | |
| ATTAGACTATGAAGATCTACAAGATCCAATTGAAAGTGGTGAAGAAATAACTTCAC | |
| AACTTGAAGAGGCAATGGATTTAATCCAAACTGTTGTAAAGAAACTAAAGATTTTA | |
| GGCGGTGACAGGTAATGTCAATAACAAACGTAGTAAAATCAGTACAAGATATAATG | |
| CGCCAGGATGCAGGGGTAGATGGAGATGCTCAAAGAATATCTCAACTAGTTTGGAT | |
| GATATTTTTAAAGGTATTTGATGCAAAAGAAGAGGAATGGGAATTAGAGTATGATG | |
| ATTATACACCTATTATTCCAGAAGAATTGAGATGGAGCAACTGGGCTCAAGATGATG | |
| AAGGAATTACAGGCGATGAGCTTTTAGACTTTGTAAACAATAAATTATTCAAAGGTT | |
| TAAAGGAAATGGAAGTAGATGAGAATAGTGATGCTAAAGCTTTATTAGTTAAATCT | |
| GTATTTGAAGATTCCTATAATTATATGAAATCAGGAGCTTTAATGAGGCAGGTAATA | |
| AATAAGTTAAATGAAATAGATTTTACAGCAGGTGAAGACAGACATTTATTTAATGAT | |
| ATATATGAAAATATATTAAAAGATCTTCAAAGTGCAGGCAATGCAGGAGAATTCTA | |
| TACACCAAGACCTGTTACACAATTTATAATAGATATGCTAAGTCCAAAGCTTGGTGA | |
| AAAAGTAGCTGACTTTGCTTGTGGTACCGGTGGATTTTTAACATGTGCCATAGAAAA | |
| CTTAAAAAAACAGGAAACCAAAGTTGAAGATTTAAAAATATTAGGTGAAACCATAA | |
| TGGGTGTAGAAAAGAAACCGCTTCCTCACATGCTTGCTACAACTAACCTGATACTTC | |
| ATGATATTGATGTGCCAAACATAAAACATGATAATTCTTTGATGAAGAATGTAAGAG | |
| ATTTAAAGCCTTCAGAATATGTGGATGTAATAGCAATGAATCCTCCTTTTGGCGGAA | |
| TTGAAGAAGATATGGTACTAACTAATTTCCCTCAGCAGTTTCAAACAAAAGAAACA | |
| GCAGATTTATTTATGACTCTTATAATGTATAGATTAAGTGAAAAAGGAAGAGCGGG | |
| AGTAGTACTTCCAGATGGATTTTTATTTGGTGAAGGTGTAAAGACTCATATAAAAGA | |
| AAAACTTTTAAATGAATTTAACCTTCATACTATAGTAAGAATGCCTAATGGAGTATT | |
| TGCCCCATATACGGGAATAAATACAAACCTTTTATTCTTTGAAAAAGGTAAGCCAAC | |
| AGAAGAAGTTTGGTTCTTTGAACATCCACTTCCTGAAGGATATAAAAATTATACTAA | |
| AACCAAACCAATAAGATATGAAGAATTTGAACTGGAGAAGAAGTGGTGGAATAACA | |
| GAGAAGAAAATGAGTATGCGTGGAAGGTTTCAGTAGAGGACATTAAAAATAGAAAT | |
| TATAATTTAGATTATAAAAATCCTAATAAGGAAGAAGAAGATTTAGGAGATCCAAA | |
| GGCATTATTAAAAAAATATCATGAAGCTGCTGCTGATGTAGATAAATTGCAAGATTC | |
| TTTGATAGATGAATTAAAGAAGATTTTAGAAGGGACATCAAAATAG | |
| SEQ ID NO: 8: Amino acid sequences of MTI-12 | |
| M N T Q E I V S K L W N L C N V L R D D G I T Y H Q Y V T E L T Y I | |
| L F L K M A K E T G T E D K L P E G Y R W D D L K V Y R G M E L K | |
| K F Y N K L L N Y L G E K T T G I V Q K I Y Q G S A T N I E E P K N | |
| L E K I I K T I D G L D W Y S A K E E G L G N L Y E G L L E K N A S | |
| E K K S G A G Q Y F T P R V L I N V M V E L I D P K P G E K C N D P | |
| A A G T F G F M I A A D R Y M K Q K T D N Y F D L G T E L Q E F Q | |
| R T K A F S G C E L V H E T H R L A L M N A M L H D I E G N I I L G | |
| D T L T N T G K Q M K D L N V V L S N P P F G T K R G G E R A T R | |
| D D L T Y M T S N K Q L N F L Q H I Y R S L K A D G K A R A A V V | |
| L P D N V L F D H N D G A K I R A D L M D K C N L H T I L R L P T G | |
| I F Y A K G V K T N V L F F T R G T S D K D N T K E V W I Y D L R T | |
| N M P S F G K T N P L K K E H F E D F I K A Y T S E D R T K V K D E | |
| R F S V F T R E E I K E K N D N L D L G L I R D E S V L D Y E D L Q | |
| D P I E S G E E I T S Q L E E A M D L I Q T V V K K L K I L G G D R | |
| M S I T N V V K S V Q D I M R Q D A G V D G D A Q R I S Q L V W M | |
| I F L K V F D A K E E E W E L E Y D D Y T P I I P E E L R W S N W A | |
| Q D D E G I T G D E L L D F V N N K L F K G L K E M E V D E N S D | |
| A K A L L V K S V F E D S Y N Y M K S G A L M R Q V I N K L N E I | |
| D F T A G E D R H L F N D I Y E N I L K D L Q S A G N A G E F Y T P | |
| R P V T Q F I I D M L S P K L G E K V A D F A C G T G G F L T C A I | |
| E N L K K Q E T K V E D L K I L G E T I M G V E K K P L P H M L A T | |
| T N L I L H D I D V P N I K H D N S L M K N V R D L K P S E Y V D V | |
| I A M N P P F G G I E E D M V L T N F P Q Q F Q T K E T A D L F M T | |
| L I M Y R L S E K G R A G V V L P D G F L F G E G V K T H I K E K L | |
| L N E F N L H T I V R M P N G V F A P Y T G I N T N L L F F E K G K | |
| P T E E V W F F E H P L P E G Y K N Y T K T K P I R Y E E F E L E K | |
| K W W N N R E E N E Y A W K V S V E D I K N R N Y N L D Y K N P | |
| N K E E E D L G D P K A L L K K Y H E A A A D V D K L Q D S L I D | |
| E L K K I L E G T S K | |
| SEQ ID NO: 9: Polynucleotide sequence of MTII-1. | |
| ATGCATAAGTGGCGTGATTTATCTATACTTGGAGAAATGTATGAAAGATCAATGGAA | |
| AAGGAAGAAAGAAAACGGAAGGGGAGTTTTTATACTCCTCATTACATAGTTGACTA | |
| TATAGTGAAGAATATTATGTCAAATTTAGATCTTAAAAAAAATCCTTTTATAAAAGT | |
| ATTAGATCCTTCTTGTGGAAGTGGATATTTTCTAGTAAGAGTATACGAAATTTTAAT | |
| GGAAAAGTTCAGTCAAAATTTAGAGCACATTAGAAATACTTTTAACGATAAAACTTA | |
| TACCATTGAAACTGAAGATGGATTAAAGAGTATAGACGGATTTCACTATTGGCAGC | |
| AGGAAAATTTAAGCTTTCATATATTAAAGAAATGTATATATGGTGCAGATATAGACA | |
| GCATCGCTGTAGAGCTTACAAAAATTAATTTAAGTAAAGTCAGTGGTATAAACATTA | |
| ATATGGAGGACAATATCATATGCTGCAACAGTCTTATAAAGTGGAATCAAATTGATA | |
| ATGTAGAAAAATATAAGGAATCTAATATTCAATCTGTTGTTAAGTTTTGGAACACAA | |
| AATATGATTATGTACTGGGGAATCCTCCTTGGGTATCTTTAAGTCGAAAGAATAAGA | |
| TGAATATAGAGGATGGATTGTTAAAGTATTATAGTGAAAATTATAATGGAAATACAT | |
| ATTTACCTAATTTGTATGAGTATTTTATAAAAAGGTCTATGGAAATATTAAAGCCGG | |
| GAGGAAGATTTGGATTTGTAGTTCCTGATAGGCTGTCACGAAATCTTCAATACAGTG | |
| AACTTAGAAAGAGTTTACTTGAAAATTATAATATATTAAATCTTGTGTTTGAGATAG | |
| ATTTTCCGGAAATAAACACAGATTCTATGATTATGATAGCAGAAAATAAACATAGA | |
| AAAGTAAATAAAATAGAAATAGATATTTATAAGAAGAGGACATATGAAATGTATCA | |
| GCATGAATATCTGAGAAATTCAAAATTTAAGTTTACATATTGTTGTTATAATCAAAA | |
| CTTAAGCATAAAGGATTGTATAGAGAAAAATAGCAGCAAATTAAAAAGCATTTCCA | |
| AGACTTTTACAGGATTTATAGGTTATAGTAAAAAAATAACTCCTGTTAAAAAAAATC | |
| AACATCAGGTTGAAGTATTAAAAGGGGAAAATATAAAAAAGTTTCGAGTTTTAAAC | |
| AATTACTATTATGATTTTGTGCCTGAAAACATAATAGGCGGAACTAAAAATATAGAA | |
| AAACTTACTTTTAAAAATAAATTAGTAATAAGGAAAACTGGAAAAAATTTAATAGC | |
| AGCTTTAGATGATAAGGGACGTATAATAGAACAATCTCTATATGGAATAATAAGTA | |
| CAAATGAGGAATTTTCACCTCAGTATATTTTGGCAATATTGAATTCAGAGTTAATTC | |
| AATGGTATTATTTAAATTTTTTAATTACCAACTCTAATTCTATTCCACAAATTAAAAA | |
| ATGCAATTTGGATGAAATACCAATAAGACATTGCAGCAGACAAGCTAAAGAAGACA | |
| TAGAAAAATTAGTTTGCAAAATTATAAATGATAATGATCAAAAAAATATGTTGAAG | |
| AAAATATTAGATGATGAGATATTTGAATTATATAATATTGATCATAATTATAGAAGA | |
| ATTATATTAAATGATATTGAAAATAA | |
| SEQ ID NO: 10: Amino acid sequence of MTII-1. | |
| M H K W R D L S I L G E M Y E R S M E K E E R K R K G S F Y T P H | |
| Y I V D Y I V K N I M S N L D L K K N P F I K V L D P S C G S G Y F | |
| L V R V Y E I L M E K F S Q N L E H I R N T F N D K T Y T I E T E D | |
| G L K S I D G F H Y W Q Q E N L S F H I L K K C I Y G A D I D S I A | |
| V E L T K I N L S K V S G I N I N M E D N I I C C N S L I K W N Q I D | |
| N V E K Y K E S N I Q S V V K F W N T K Y D Y V L G N P P W V S L | |
| S R K N K M N I E D G L L K Y Y S E N Y N G N T Y L P N L Y E Y F I | |
| K R S M E I L K P G G R F G F V V P D R L S R N L Q Y S E L R K S L | |
| L E N Y N I L N L V F E I D F P E I N T D S M I M I A E N K H R K V | |
| N K I E I D I Y K K R T Y E M Y Q H E Y L R N S K F K F T Y C C Y N | |
| Q N L S I K D C I E K N S S K L K S I S K T F T G F I G Y S K K I T P | |
| V K K N Q H Q V E V L K G E N I K K F R V L N N Y Y Y D F V P E N | |
| I I G G T K N I E K L T F K N K L V I R K T G K N L I A A L D D K G | |
| R I I E Q S L Y G I I S T N E E F S P Q Y I L A I L N S E L I Q W Y Y L | |
| N F L I T N S N S I P Q I K K C N L D E I P I R H C S R Q A K E D I E | |
| K L V C K I I N D N D Q K N M L K K I L D D E I F E L Y N I D H N Y | |
| R R I I L N D I E N * | |
| SEQ ID NO: 11: Ppta-ack-MTII-1. | |
| TGCCTAAGTGAAATATATACATATTATAACAATAAAATAAGTATTAGTGTAGGATTT | |
| TTAAATAGAGTATCTATTTTCAGATTAAATTTTTGATTATTTGATTTACATTATATAA | |
| TATTGAGTAAAGTATTGACTAGCAAAATTTTTTGATACTTTAATTTGTGAAATTTCTT | |
| ATCAAAAGTTATATTTTTGAATAATTTTTATTGAAAAATACAACTAAAAAGGATTAT | |
| AGTATAAGTGTGTGTAATTTTGTGTTAAATTTAAAGGGAGGAAA | |
| ATGCATAAGTGGCGTGATTTATCTATACTTGGAGAAATGTATGAAAGATCAATGGAA | |
| AAGGAAGAAAGAAAACGGAAGGGGAGTTTTTATACTCCTCATTACATAGTTGACTA | |
| TATAGTGAAGAATATTATGTCAAATTTAGATCTTAAAAAAAATCCTTTTATAAAAGT | |
| ATTAGATCCTTCTTGTGGAAGTGGATATTTTCTAGTAAGAGTATACGAAATTTTAAT | |
| GGAAAAGTTCAGTCAAAATTTAGAGCACATTAGAAATACTTTTAACGATAAAACTTA | |
| TACCATTGAAACTGAAGATGGATTAAAGAGTATAGACGGATTTCACTATTGGCAGC | |
| AGGAAAATTTAAGCTTTCATATATTAAAGAAATGTATATATGGTGCAGATATAGACA | |
| GCATCGCTGTAGAGCTTACAAAAATTAATTTAAGTAAAGTCAGTGGTATAAACATTA | |
| ATATGGAGGACAATATCATATGCTGCAACAGTCTTATAAAGTGGAATCAAATTGATA | |
| ATGTAGAAAAATATAAGGAATCTAATATTCAATCTGTTGTTAAGTTTTGGAACACAA | |
| AATATGATTATGTACTGGGGAATCCTCCTTGGGTATCTTTAAGTCGAAAGAATAAGA | |
| TGAATATAGAGGATGGATTGTTAAAGTATTATAGTGAAAATTATAATGGAAATACAT | |
| ATTTACCTAATTTGTATGAGTATTTTATAAAAAGGTCTATGGAAATATTAAAGCCGG | |
| GAGGAAGATTTGGATTTGTAGTTCCTGATAGGCTGTCACGAAATCTTCAATACAGTG | |
| AACTTAGAAAGAGTTTACTTGAAAATTATAATATATTAAATCTTGTGTTTGAGATAG | |
| ATTTTCCGGAAATAAACACAGATTCTATGATTATGATAGCAGAAAATAAACATAGA | |
| AAAGTAAATAAAATAGAAATAGATATTTATAAGAAGAGGACATATGAAATGTATCA | |
| GCATGAATATCTGAGAAATTCAAAATTTAAGTTTACATATTGTTGTTATAATCAAAA | |
| CTTAAGCATAAAGGATTGTATAGAGAAAAATAGCAGCAAATTAAAAAGCATTTCCA | |
| AGACTTTTACAGGATTTATAGGTTATAGTAAAAAAATAACTCCTGTTAAAAAAAATC | |
| AACATCAGGTTGAAGTATTAAAAGGGGAAAATATAAAAAAGTTTCGAGTTTTAAAC | |
| AATTACTATTATGATTTTGTGCCTGAAAACATAATAGGCGGAACTAAAAATATAGAA | |
| AAACTTACTTTTAAAAATAAATTAGTAATAAGGAAAACTGGAAAAAATTTAATAGC | |
| AGCTTTAGATGATAAGGGACGTATAATAGAACAATCTCTATATGGAATAATAAGTA | |
| CAAATGAGGAATTTTCACCTCAGTATATTTTGGCAATATTGAATTCAGAGTTAATTC | |
| AATGGTATTATTTAAATTTTTTAATTACCAACTCTAATTCTATTCCACAAATTAAAAA | |
| ATGCAATTTGGATGAAATACCAATAAGACATTGCAGCAGACAAGCTAAAGAAGACA | |
| TAGAAAAATTAGTTTGCAAAATTATAAATGATAATGATCAAAAAAATATGTTGAAG | |
| AAAATATTAGATGATGAGATATTTGAATTATATAATATTGATCATAATTATAGAAGA | |
| ATTATATTAAATGATATTGAAAATAA |
Claims (12)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/592,208 US9428755B2 (en) | 2013-03-13 | 2015-01-08 | Use of clostridial methyltransferases for generating novel strains |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361780731P | 2013-03-13 | 2013-03-13 | |
| US14/209,634 US9045758B2 (en) | 2013-03-13 | 2014-03-13 | Use of clostridial methyltransferases for generating novel strains |
| US14/592,208 US9428755B2 (en) | 2013-03-13 | 2015-01-08 | Use of clostridial methyltransferases for generating novel strains |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US14/209,634 Continuation US9045758B2 (en) | 2013-03-13 | 2014-03-13 | Use of clostridial methyltransferases for generating novel strains |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| US20150191736A1 US20150191736A1 (en) | 2015-07-09 |
| US9428755B2 true US9428755B2 (en) | 2016-08-30 |
Family
ID=51528853
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US14/209,634 Active US9045758B2 (en) | 2013-03-13 | 2014-03-13 | Use of clostridial methyltransferases for generating novel strains |
| US14/592,208 Active US9428755B2 (en) | 2013-03-13 | 2015-01-08 | Use of clostridial methyltransferases for generating novel strains |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US14/209,634 Active US9045758B2 (en) | 2013-03-13 | 2014-03-13 | Use of clostridial methyltransferases for generating novel strains |
Country Status (2)
| Country | Link |
|---|---|
| US (2) | US9045758B2 (en) |
| WO (1) | WO2014160343A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2688486C2 (en) * | 2014-01-16 | 2019-05-21 | Калиста, Инк. | Microorganisms for high production of amino acids and related methods |
| CN111621510B (en) * | 2019-02-27 | 2024-01-05 | 南京食气生化科技有限公司 | Optimized clostridium Yankeei exogenous DNA electrotransformation method |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008028055A2 (en) | 2006-08-31 | 2008-03-06 | The Board Of Regents For Oklahoma State University | Isolation and characterization of novel clostridial species |
| WO2009137778A2 (en) | 2008-05-08 | 2009-11-12 | Northwestern University | Methods and compositions for genetically engineering clostridia species |
| US7820408B2 (en) | 2006-11-29 | 2010-10-26 | Novozymes, Inc. | Methods of improving the introduction of DNA into bacterial cells |
| US20110229947A1 (en) | 2010-03-19 | 2011-09-22 | Coskata, Inc. | Novel Ethanologenic Clostridium species, Clostridium coskatii |
| US20110236941A1 (en) | 2010-10-22 | 2011-09-29 | Lanzatech New Zealand Limited | Recombinant microorganism and methods of production thereof |
| WO2012105853A1 (en) | 2011-02-02 | 2012-08-09 | Lanzatech New Zealand Limited | Recombinant microorganisms with increased tolerance to ethanol |
| US20120270297A1 (en) | 2011-03-28 | 2012-10-25 | Bowling Green State University | Culturing and genetic manipulations of thermotoga spp. |
-
2014
- 2014-03-13 US US14/209,634 patent/US9045758B2/en active Active
- 2014-03-13 WO PCT/US2014/026350 patent/WO2014160343A1/en not_active Ceased
-
2015
- 2015-01-08 US US14/592,208 patent/US9428755B2/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008028055A2 (en) | 2006-08-31 | 2008-03-06 | The Board Of Regents For Oklahoma State University | Isolation and characterization of novel clostridial species |
| US7820408B2 (en) | 2006-11-29 | 2010-10-26 | Novozymes, Inc. | Methods of improving the introduction of DNA into bacterial cells |
| WO2009137778A2 (en) | 2008-05-08 | 2009-11-12 | Northwestern University | Methods and compositions for genetically engineering clostridia species |
| US20110229947A1 (en) | 2010-03-19 | 2011-09-22 | Coskata, Inc. | Novel Ethanologenic Clostridium species, Clostridium coskatii |
| US20110236941A1 (en) | 2010-10-22 | 2011-09-29 | Lanzatech New Zealand Limited | Recombinant microorganism and methods of production thereof |
| WO2012105853A1 (en) | 2011-02-02 | 2012-08-09 | Lanzatech New Zealand Limited | Recombinant microorganisms with increased tolerance to ethanol |
| US20120270297A1 (en) | 2011-03-28 | 2012-10-25 | Bowling Green State University | Culturing and genetic manipulations of thermotoga spp. |
Non-Patent Citations (14)
| Title |
|---|
| Abrini J, et al., 1994, Arch. Microbiol. , 4:345-351. |
| Allen and Blaschek, 1990, FEMS Microbiology Letters, 58:217. |
| Antoine and Locht., 1992, Mol. Microbiol. 6(13): 1785-1799. |
| de Feyter et al., 1991, Journal of Bacteriology, 173:6421-6427. |
| International Search Report for International application No. PCT/US2014/026350, mailed Sep. 1, 2014. 5 pages. |
| Kennaway et al., 2009, Nucleic Acids Research, 37(3):762-770. |
| Leang, et al., 2012, Applied and Environmental Microbiology, Epub ahead of print Nov. 30, 2012. |
| Mann et al., 1978, Gene 3:97-102. |
| Mermelstein et al., 1993, Applied and Environmental Microbiology, 59:1077-1081. |
| NCBI , NCBI Reference Sequence No: WP-001064588.1, Feb. 5, 2013 1 page. |
| Parke D, 1990, Gene, 93(1): 135-137. |
| Suzuki, 2012, InTech, Host-mimicking strategies in DNA methylation for improved bacterial transformation in Methyulation-from DNA, RNA and histones to diseases and treatment, 219-236. |
| Weisblum et al., 1979, Journal of Bacteriology, p. E194, 137:635-643. |
| Written Opinion for International application No. PCT/US2014/026350, mailed Sep. 1, 2014. 6 pages. |
Also Published As
| Publication number | Publication date |
|---|---|
| US20150191736A1 (en) | 2015-07-09 |
| US9045758B2 (en) | 2015-06-02 |
| US20140273236A1 (en) | 2014-09-18 |
| WO2014160343A1 (en) | 2014-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2011357608B2 (en) | Recombinant microorganisms with increased tolerance to ethanol | |
| Aagaard et al. | General vectors for archaeal hyperthermophiles: strategies based on a mobile intron and a plasmid | |
| US12331326B2 (en) | Genetically engineered Vibrio sp. and uses thereof | |
| Zhang et al. | I-SceI-mediated scarless gene modification via allelic exchange in Clostridium | |
| US20130224839A1 (en) | Recombinant Microorganism and Methods of Production Thereof | |
| JP2018500920A (en) | Suicidal vectors for gene knockout commonly used in Vibrio and their use | |
| EP2041288B1 (en) | Rk2-based broad-host-range cloning vector useful for transfer of metagenomic libraries to a variety of bacterial species | |
| CN105821071A (en) | Unmarked gene knock-out method of pediococcus acidilactici DQ2 based on homologous recombination | |
| CN102154188A (en) | nfi-gene-knocked-out mutant strain of escherichia coli DH5 alpha as well as preparation method and application thereof | |
| Crombie et al. | Development of a system for genetic manipulation of the facultative methanotroph Methylocella silvestris BL2 | |
| Sakanaka et al. | A transposon mutagenesis system for Bifidobacterium longum subsp. longum based on an IS 3 family insertion sequence, IS Blo11 | |
| Uraji et al. | A novel plasmid curing method using incompatibility of plant pathogenic Ti plasmids in Agrobacterium tumefaciens | |
| Owen et al. | Physical structure, genetic content and expression of the alkBAC operon | |
| US9428755B2 (en) | Use of clostridial methyltransferases for generating novel strains | |
| CN103215215A (en) | Escherichia coli expression strain with high conversion efficiency | |
| JP2022516025A (en) | Preparation and use of genetically modified Clostridium bacteria. | |
| US9745566B2 (en) | Recombinant microorganisms and methods of use thereof | |
| US8927254B2 (en) | Pyrococcus furiosus strains and methods of using same | |
| JP4904444B2 (en) | Shuttle vector | |
| US9267106B2 (en) | Method for incorporation of recombinant DNA | |
| Chaiboripan et al. | Steps Toward Developing an Antisense RNA Construct for surA in Escherichia coli | |
| CN104673731A (en) | Method for optimizing xylose utilization rate of clostridium acetobutylicum | |
| CN114231547A (en) | Novel application of CRISPR/Cas9 system | |
| JP4903004B2 (en) | Methods for transforming bacteria belonging to the genus Rhodococcus | |
| Yang et al. | Repurposing endogenous Type ID CRISPR-Cas system for genome editing in Synechococcus sp. PCC7002 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: COSKATA, INC., ILLINOIS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:REEVES, ANDREW;REEL/FRAME:036605/0949 Effective date: 20150213 |
|
| AS | Assignment |
Owner name: VINOD KHOSLA AND NEERU KHOSLA, TRUSTEES OF THE KFT Free format text: SECURITY INTEREST;ASSIGNOR:COSKATA, INC.;REEL/FRAME:036933/0596 Effective date: 20151021 Owner name: ATV ENTREPRENEURS VII, LP, MASSACHUSETTS Free format text: SECURITY INTEREST;ASSIGNOR:COSKATA, INC.;REEL/FRAME:036933/0596 Effective date: 20151021 Owner name: KHOSLA VENTURES III, LP, CALIFORNIA Free format text: SECURITY INTEREST;ASSIGNOR:COSKATA, INC.;REEL/FRAME:036933/0596 Effective date: 20151021 Owner name: ADVANCED TECHNOLOGY VENTURES VII (B), L.P., MASSAC Free format text: SECURITY INTEREST;ASSIGNOR:COSKATA, INC.;REEL/FRAME:036933/0596 Effective date: 20151021 Owner name: ADVANCED TECHNOLOGY VENTURES VII (C), L.P., MASSAC Free format text: SECURITY INTEREST;ASSIGNOR:COSKATA, INC.;REEL/FRAME:036933/0596 Effective date: 20151021 Owner name: ADVANCED TECHNOLOGY VENTURES VII, L.P., MASSACHUSE Free format text: SECURITY INTEREST;ASSIGNOR:COSKATA, INC.;REEL/FRAME:036933/0596 Effective date: 20151021 |
|
| AS | Assignment |
Owner name: COSKATA, INC., ILLINOIS Free format text: RELEASE BY SECURED PARTY;ASSIGNORS:VINOD KHOSLA AND NEERU KHOSLA, TRUSTEES OF THE KFT TRUST DATED NOVEMBER 17, 1986;KHOSLA VENTURES III, LP;ADVANCED TECHNOLOGY VENTURES VII, L.P.;AND OTHERS;REEL/FRAME:037153/0659 Effective date: 20151021 |
|
| AS | Assignment |
Owner name: SYNATA BIO, INC., ILLINOIS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:COSKATA, INC.;REEL/FRAME:038709/0722 Effective date: 20151116 |
|
| STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
| AS | Assignment |
Owner name: SYNATA BIO, INC., ILLINOIS Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR PREVIOUSLY RECORDED ON REEL 038709 FRAME 0722. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNOR:COSKATA, LLC;REEL/FRAME:044310/0659 Effective date: 20151116 |
|
| MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2551); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Year of fee payment: 4 |
|
| MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2552); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Year of fee payment: 8 |